What's Going On With Spyre Therapeutics Stock On Wednesday?

Benzinga_recent_news06-24

The stock is up more than 160% year to date and over 450% over the past year. In a separate transaction on Monday, director Michael Thomas Henderson sold 20,000 shares. In June, Spyre Therapeutics ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2646122308?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/cdn-cgi/image/width=240,format=auto,quality=85/files/images/story/2026/06/24/Trading-Investment-Charts--Investment-Fi.jpg","is_english":true,"pubTime":"2026-06-24 23:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2646122308","market":"us","top_or_hot":-1,"title":"What's Going On With Spyre Therapeutics Stock On Wednesday?","media":"Benzinga_recent_news","content":"<div>\n<p>The stock is up more than 160% year to date and over 450% over the past year.\nIn a separate transaction on Monday, director Michael Thomas Henderson sold 20,000 shares.\nIn June, Spyre Therapeutics ...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/insider-trades/26/06/60076083/whats-going-on-with-spyre-therapeutics-stock-on-wednesday\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What's Going On With Spyre Therapeutics Stock On Wednesday?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat's Going On With Spyre Therapeutics Stock On Wednesday?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-24 23:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/trading-ideas/insider-trades/26/06/60076083/whats-going-on-with-spyre-therapeutics-stock-on-wednesday><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The stock is up more than 160% year to date and over 450% over the past year.\nIn a separate transaction on Monday, director Michael Thomas Henderson sold 20,000 shares.\nIn June, Spyre Therapeutics ...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/insider-trades/26/06/60076083/whats-going-on-with-spyre-therapeutics-stock-on-wednesday\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4130","symbol_name":"人力资源与就业服务","start_time":0,"source_url":"https://www.benzinga.com/trading-ideas/insider-trades/26/06/60076083/whats-going-on-with-spyre-therapeutics-stock-on-wednesday","article_id":"2646122308","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/cdn-cgi/image/width=240,format=auto,quality=85/files/images/story/2026/06/24/Trading-Investment-Charts--Investment-Fi.jpg"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/insider-trades/26/06/60076083/whats-going-on-with-spyre-therapeutics-stock-on-wednesday","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2646122308","pubTimestamp":1782316560,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Spyre Therapeutics falls 12% amid major insider stock sales. Explore the technical data and market sentiment for SYRE.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4130":"人力资源与就业服务","BK4007":"制药","RHI":"罗致恒富","BK4588":"碎股","LENZ":"Therapeutics","BK4539":"次新股","LU0054578231.USD":"BGF SYSTEMATIC SUSTAINABLE GLOBAL SMALLCAP \"A2\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4585":"ETF&股票定投概念","BK4139":"生物科技"},"translate_title":"周三Spyre Therapeutics股票走势如何？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RHI":1,"LENZ":1.5},"content_text":"The stock is up more than 160% year to date and over 450% over the past year.\nIn a separate transaction on Monday, director Michael Thomas Henderson sold 20,000 shares.\nIn June, Spyre Therapeutics shared positive 12-week induction data from Part A of the Phase 2 SKYLINE trial of SPY002 for moderately-to-severely active ulcerative colitis (UC).\nSPY002 met its primary endpoint with a statistically significant reduction of 10.7 points (p<0.0001) from baseline at Week 12 in Robart’s Histopathology Index (RHI) score.\nSecondary endpoints included clinical remission by the modified Mayo Score of 33% and endoscopic improvement of 42%.\nIn April, the clinical-stage biotechnology company released positive results from the Phase 2 SKYLINE trial for SPY001 for UC, which met its primary endpoint with a statistically significant reduction in the Robart’s Histopathology Index score.\nSoon after the positive trial data, Spyre Therapeutics raised approximately $463.5 million in gross proceeds from a public offering of 7.475 million shares at $62/share.\nSpyre Therapeutics’ stock is currently showing a strong bullish trend, trading well above its key moving averages. The 20-day SMA is positioned 7.4% above the 50-day SMA, and both the 50-day and 200-day SMAs indicate a solid long-term bullish trend.\nWith the RSI at 60.48, the stock is in neutral territory, suggesting that while momentum is positive, it isn’t yet overbought. This level indicates that there could still be room for upward movement before hitting overbought conditions.\nThe MACD is above its signal line, indicating bullish momentum for Spyre Therapeutics, Inc. This suggests that traders may want to look for potential buying opportunities as the trend remains strong.\nTraders should keep an eye on the support level at 68.50, as a drop below this could signal a trend change. Conversely, if the stock continues to hold above this level, it may indicate a continuation of the current bullish trend.\nSpyre Therapeutics’ stock has not experienced a golden cross or death cross recently, but the current moving average relationships are bullish. The 50-day SMA is above the 200-day SMA, reinforcing the long-term upward trend.\nSYRE Stock Price Activity: Spyre Therapeutics shares were down 11.72% at $85.67 at the time of publication on Wednesday, according to Benzinga Pro data.\nImage via Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2646122308","isCrawlerRequest":true}